Last reviewed · How we verify
KN060
At a glance
| Generic name | KN060 |
|---|---|
| Sponsor | Suzhou Alphamab Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients (PHASE1, PHASE2)
- To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension (PHASE1)
- Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KN060 CI brief — competitive landscape report
- KN060 updates RSS · CI watch RSS
- Suzhou Alphamab Co., Ltd. portfolio CI